Cargando…
Variation in Adherence Measures to Imatinib Therapy
PURPOSE: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studie...
Autores principales: | Yanamandra, Uday, Malhotra, Pankaj, Sahu, K.K., Sushma, Yanamandra, Saini, Neha, Chauhan, Pooja, Gill, Jasmeen, Rikhi, Deepika, Khadwal, Alka, Prakash, Gaurav, Lad, Deepesh, Suri, Vikas, Kumari, Savita, Varma, Neelam, Varma, Subhash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223484/ https://www.ncbi.nlm.nih.gov/pubmed/30241224 http://dx.doi.org/10.1200/JGO.2016.007906 |
Ejemplares similares
-
Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023) -
Chronic Lymphocytic Leukemia: Real-World Data From India
por: Tejaswi, V., et al.
Publicado: (2020) -
Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
por: Prakash, Gaurav, et al.
Publicado: (2021) -
How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
por: Jain, Arihant, et al.
Publicado: (2020) -
Cytopathological Diagnosis of an Unusual Cause of Malignant Hydrocele
por: Jain, Ankur, et al.
Publicado: (2016)